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Introduction and importance: Gestational trophoblastic disease is an uncommon group of pregnancy-related dis
orders, with a course of trophoblastic proliferation, including hydatidiform mole (Agha et al., 2020), invasive
and metastatic mole, choriocarcinoma, placental-site trophoblastic tumor, and epithelial trophoblastic tumor.
Choriocarcinoma and trophoblastic tumor of the placenta are the most important tumors associated with
pregnancy.
Case findings: A 52-year-old woman Para 2 Living 3, 3 years post-menopausal presented with prolong per vaginal
bleeding for five weeks accompanied by lower abdominal pain. Diagnosis of gestational trophoblastic disease
(choriocarcinoma type) was made by using beta HCG, radiology, and histology report. Patient underwent total
abdominal hysterectomy and bilateral salphingo-opherectomy, followed by 2 cycles of chemotherapy.
Discussion: Trophoblast disease of pregnancy disease includes a unique tissue group with a wide range of
endocrine and angiogenic functions derived from placental trophoblasts. They are associated with uncommon,
interrelated conditions, which differ according to the following parameters: invasion, regression, metastasis, and
recurrence rate. Beta HCG remains initial investigation to be taken in patients suspecting trophoblastic disease.
Conclusion and recommendations: Gestational trophoblastic disease should be considered in the differential
diagnosis of peri and postmenopausal vaginal bleeding. Long term follows up with beta HCG needs to be done to
detect recurrence.

1. Introduction
The trophoblast is a unique tissue, with special morphological and
immunohistochemical characteristics related to its various metabolic,
endocrine and angiogenetic functions [2]. Infiltration and metastasis are
the main criteria for the diagnosis of a malignant tumor, but these
criteria cannot be applied in the case of trophoblast, as they are normal
features of this tissue, whose role is to infiltrate the endometrium, the
underlying myometrium and parent vessels [2].
Trophoblast cells are an important parameter for the formation of
placental tissue. Their role is to promote the penetration of the fetus
inside the uterus to penetrate the uterine blood vessels, to induce
angiogenesis and to produce human chorionic gonadotropin. Tropho
blast is enrolled in three-layer types of cells: a) Cytotrophoblast or
Langhans cells internal layer, b) intermediate trophoblastic cells mid

layer and c) and an external layer of syncytiotrophoblastic cells [3].
Cytotrophoblastic cells are small, round mononuclear cells with
distinct cell borders, minimal clear or eosinophilic cytoplasm and ve
sicular nuclei. Intermediate trophoblasts are larger than cytotropho
blasts, polygonal with abundant clear cytoplasm, distinct cell borders
and single nuclei. Syncytiotrophoblasts are multinucleated giant cells
with eosinophilic or basophilic cytoplasm and dense, large, pyknotic
nuclei [4].
Syncytiotrophoblasts infiltrate the myometrium to ensure the suc
cessful implantation and proper nutrition of the fetus. This invasion
process seems to be regulated mainly by the mechanism of apoptosis,
which, in its turn, is controlled by the balance of two proteins belonging
to the same protein family: bcl-2 protein, which demotes apoptosis and
bax protein, which promotes it [5].
Gestational trophoblastic disease is an uncommon group of
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pregnancy-related disorders, with a course of trophoblastic prolifera
tion, including hydatidiform mole (HM), invasive and metastatic mole,
choriocarcinoma, placental-site trophoblastic tumor, and epithelial
trophoblastic tumor [6].
Choriocarcinoma and trophoblastic tumor of the placenta are the
most important tumors associated with pregnancy [7]. Choriocarcinoma
is an extremely aggressive tumor that originates in the trophoblast of
any gestational age [8].
Similar to pregnancy, the change from hCG production to hPL re
flects and confirms the maturation of trophoblastic tissue [8]. The same
theory applies to choriocarcinoma which is considered an immature
tumor with very aggressive growth and early metastases [8].
Based on histological findings of the hysterectomy and bilateral
oopherectomy, salpingectomy and HCG titer, in order to contribute to
the scientific experience and further understand gestational choriocar
cinoma, we reviewed the medical record of a 51-year-old woman with
gestational choriocarcinoma, 30 years after her last normal deliver
3 years after her last menstrual period. This paper has been reported in
line with the SCARE 2020 criteria [1]. This article has been registered
with the Research Registry with identification number researchregis
try8060 and can be found through the following hyperlink Browse the
Registry - Research Registry.

Fig. 1. Uterine contents from the vaginal contained blood, multiple small
vesicles mixed with minimal clots.

2. Case presentation
A 52-year-old woman Para 2 Living 3 present in Family Medicine
Clinic with prolong per vaginal bleeding for five weeks accompanied by
lower abdominal pain. Attained menarche 3 years ago. Initially the
bleeding was minimal, progressed to heavy flow soaking at least 4 ma
ternity pads per day. She reported increase in lower abdominal girth
reaching the umbilical level. Furthermore, she noticed to have lost
weight and experienced heart burn, easy fatigue, shortness of breath as
well as awareness of her heartbeats.
She denies any history of hot flushes or heat intolerance. She re
ported being seen in other facilities where the impression of symptom
atic fibroid was made and she was given medication, however there was
no relief.
She had regular menstrual cycle of 30 days duration lasting for 4 to
5 days. The menstrual flow was normal. Last delivery was 30 years ago,
and she has history of using injectable contraceptives. However, she
then used intrauterine contraceptive device (copper T), then changed to
calendar method. She has been taking Primrose evening oil tablet daily
for six months.
She otherwise had no significant family history of disease, no drug
allergies and did not smoke or drink alcohol.
On admission she was pale and tachycardia, the abdomen was
symmetrical distended, old healed SUMI scar, soft abdomen but firm
uterine fundus palpable at umbilical level (20 cm), mild tenderness on
the supra pubic, liver and spleen not enlarged, and kidneys were not
ballotable.
Speculum reveal normal perineum, visible stained sanitary pad with
blood, vaginal walls and cervix mucosa was health, a visible bleeding
seen from the cervical external os. Other systemic examinations were
essentially normal.
Patient was admitted in the ward with diagnosis of bleeding fibroids
while in the ward waiting for the ultrasound scan, she suddenly expelled
uterine content with vesicles, which was later sent for histological ex
amination (Fig. 1). Ultrasound scan reveal endometrium thickened of
5.2 cm, large hyperechoic heterogeneous lesion (bunch of grapes) with
cystic changes which measure 13.3 × 6.8 cm, no vascularity appreciated
(Fig. 2).
Initial labs results were as follows: White cell count of 11 × 109/l,
hemoglobin 11.1 g/dl, platelets 184 × 109/l when compare with com
plete blood count post expulsion of uterine products white cell count of
10.2 × 109/l, hemoglobin 9.4 g/dl and platelets were 114 × 109/l.
Other laboratory parameters were CA 125 (serum) 44.78 U/ml

Fig. 2. Below ultrasound scan reveal endometrium thickened of 5.2 cm bunch
of grapes 13.3 × 6.8 cm, no vascularity appreciated.

(0–35.0), free T3 (serum) 8.11 pmol/l (3.10–6.8), free T4 (serum)
39.27 pmol/l (12.0–22.0), thyroid stimulating hormone (serum)
0.013 μIU/ml (0.270–4.20), FSH (serum) 0.100 mIU/ml <0.1 meno
pausal range, and beta HCG (serum) 680,058 mIU/ml <0.01 meno
pausal range.
From the laboratory parameters it highly suggestive of molar preg
nancy with hyperthyroidism mimic elements from as it presented from
levels of thyroid stimulating hormone and free T4 levels.
Histology results showed hydatiform mole (Fig. 3). Chest X ray and
MRI of the abdomen were done to look for the sign of metastasis were
done which were normal.
A final diagnosis of gestation trophoblastic tumor with a score of ≥7
(according to FIGO risk score and GTN staging) [9]. Tumor board de
cision was made to start EMA-CO (etoposide, methotrexate, actinomycin
D, cyclophosphamide, vincristine) chemotherapy, but the patient
refused due to fear of side effects of chemotherapy. However, later pa
tient consented for total abdominal hysterectomy and bilateral sal
pingectomy and all organs were sent to lab. Post operative Oncologist
teams were consulted and initiate 2 cycles of EMA-CO.
Post total abdominal hysterectomy and bilateral salpingectomy bi
opsy showed leiomyomata uteri, trophoblastic disease (chorionic car
cinoma) and corpus luteal cyst (Fig. 4).
Beta human chorionic gonadotropin (BHCG) weekly follows up till
14th week is as shown in the graph (Fig. 5).
3. Discussion
A patient age at 52 years old obscured our attention on the possibility
2
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Fig. 3. Below histology showing biopsy results from the uterine content products.

Fig. 4. Below post total abdominal hysterectomy and bilateral salpingectomy organs biopsy.
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Fig. 5. Below chart showing decrease of BHCG versus corresponding week of measure.

of neither normal pregnant nor molar pregnant. It is very rare to
encounter such a case unless in a history of attempted intra vitro
fertilization. This had led to delayed diagnosis and initiation of treat
ment in the first hospital she attended. Majority of perimenopausal or
postmenopausal women do present in our setting with abnormal vaginal
bleeding due to endometrial hyperplasia, endometrial cancer, and

cervical cancer.
Trophoblast disease of pregnancy or gestational trophoblastic dis
ease includes a unique tissue group with a wide range of endocrine and
angiogenic functions derived from placental trophoblasts [10]. They are
associated with uncommon, interrelated conditions, which differ ac
cording to the following parameters: invasion, regression, metastasis
3
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and recurrence rate [11].
Gestational trophoblastic neoplasia occurs most commonly in
reproductive age after antecedent gestational events, like recent preg
nancy usually within a year of a preceding pregnancy or more decades in
the past, molar or non-pregnancy in 50 % of the cases, abortions, ectopic
pregnancies also recently or after a long time in the past, while only a
few cases have been reported in the international literature [7,17]. In
complete molar pregnancies the classical occurrence of large edematous
clusters of vesicles with hemorrhage and necrosis is typical. The ma
jority karyotype of complete molar pregnancies are 46XX in 95 % of
cases arise from fertilization of an empty pronucleus by haploid sperm
that undergoes duplication, Diandric diploidy, while the minority are 46
XY in 5 % of cases which arise from fertilization of an empty egg by two
sperm and led to Diandric dispermy. Partial mole is associated to less
abundant hydropic villi large edematous with stromal fibrosis [12].
Gestational trophoblastic disease is the appropriate collective name
but interrelated pathological conditions derived from placental tro
phoblasts for partial, complete molar pregnancy (both characterized by
the presence of hydropic villi which usually contain fetal vessels and
fetal red blood cells), miscellaneous trophoblastic tumors (exaggerated
placental site, placental site nodule or plaque),unclassified trophoblastic
lesions, choriocarcinoma and placental site trophoblastic tumor [11,17].
Gestational choriocarcinoma can occur by any gestational event as
follows: after hydatidiform mole in 50 % of cases, 25 % after sponta
neous abortion, 22.5 % after normal pregnancy and 2.5 % after ectopic
pregnancy (1 in 5333 tubal pregnancies) [13]. Not always to the pre
disponding pregnancy within the uterine cavity is referred as one of the
most related factors within a year of the referred pregnancy [13].
Especially in the premenopausal women gestational trophoblastic pa
thology is subsequent hydatid mole in 60 % of cases, abortions in 30 %
and in 10 % normal or ectopic pregnancy. While in Europe and North
America the occurrence is 30,000–40,000 intrauterine and 1/40 molar
pregnancies, the rates increase to 1/500–3000 in south East Asia [13]. In
Sub Saharan African countries has limited data in gestational
choriocarcinoma.
Tsukamoto et al. reported 20 women of GTD (≥50 years), none of
whom were diagnosed with complete hydatiform molar. In China, Feng
et al. reviewed 38 cases of GTD in women aged 50 years or more, of
whom 19 had invasive moles, five were HM patients, 12 were chorio
carcinomas patients, and two had placenta-site trophoblastic disease
[14].
There are about 14 cases [15] in the global literature concerning
choriocarcinoma in the postmenopausal period. Based on these cases,
the most common symptoms of choriocarcinoma in postmenopausal
women are vaginal bleeding (approximately 80 %), uterine enlargement
(100 %), abdominal pain (42 %), and nausea and vomiting (25 %), as
well as markedly elevated serum β-HCG level. This is similar as it pre
sented in our case.
The choriocarcinomas, which are highly vascular neoplasms have as
main clinical presentation abnormal uterine bleeding and metastasize
readily in approximately 30 % of cases at the time of the final diagnosis
and most commonly in lung 60–75 %, vagina 40–50 %, brain 15–20 %,
liver 15–20 %, spleen 10 %, intestines 10 % (5 % bowel metastasis), and
central nervous system involvement in 10 % of cases, very rare mani
festation, 4 % in cardiac intracavity mass, cardiac metastasis [14,16]. In
our case, we did MRI of the abdomen and chest X ray which turn to be
normal, and patient had no sign of metastasize.
Initial diagnosis is based on multimodality approach like considering
clinical features; serial beta HCG titers and pelvic imaging-like ultraso
nography and MRI. The most possible reason for delayed diagnosis of
GTD in perimenopausal age group could be the absence of suspicion of
pregnancy in them. Evidence suggests that incidence of choriocarci
noma had decreased due to strict follow up of patients with molar
pregnancy [16]. This is similar to our case were the initial beta HCG
were 680,058 mIU/ml which followed by spontaneous expulsion of
vesicle like product from the vagina thus lead to diagnosis of gestational

trophoblastic disease to be high in the list.
Ultrasound is first line of imaging. The appearance of lesion is clas
sically described as snowstorm/granular appearance due to multiple
echogenic foci [16]. This is similar to our case whereby initial ultra
sound showed thickened endometrial wall and bunch of grades in the
uterine cavity which is highly suggestive of gestational trophoblastic
disease.
Pelvic MRI is used to assess depth of myometrial invasion and extra
uterine spread in equivocal and complicated cases. Chest radiography,
PET CT or brain MRI has been recommended as investigative tools for
overall staging of the disease. Angiography has a role in management of
disease complications with metastasis [13,16].
In our case, the indication of confirmation gestational choriocarci
noma was based on high β-hCG serum levels, radiology findings and
histological evident findings comprising of leiomyomata uteri, chorionic
carcinoma, and corpus luteal cyst. Due to high-risk score and early stage
according to FIGO staging we recommended EMA-CO chemotherapy
regime, but initially patient refused due to fear of side effects of
chemotherapy however later patient was sent for total abdominal hys
terectomy and bilateral salphio-oopherectomy and later receive 2 cycle
of EMA-CO this decision was based on international oncology treatment
protocols. Post chemotherapy level of beta HCG decrease dramatically
to undetectable level in week 14 after surgery and 2 cycle of
chemotherapy.
This reported case is of clinical importance due to the patient’s long
30-year period after her last gestational event age of patient 3 years
postmenopausal long time after last gestational event. Generally, the
prognostic value in reproductive time of the long duration between last
gestation event and tumor diagnosis is negative associated to poor
prognosis, however in the postmenopausal time unknown, possible
poor.
4. Conclusion and recommendation
GTD should be considered in the differential diagnosis of peri and
postmenopausal vaginal bleeding. In menopausal women, definitive
treatment should be hysterectomy owing to high risk of malignancy. A
high level of suspicion should be included in differential diagnosis of
peri menopausal bleeding to prevent delay in diagnosis and treatment.
Long term follows up with beta HCG needs to be done to detect
recurrence.
Abbreviations
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